Business
TODAY: Gb Sciences' Novel Plant-Inspired Pain Medications Featured at SMi's 22nd Annual Pain Therapeutics Conference
TODAY: Gb Sciences' Novel Plant-Inspired Pain Medications Featured at SMi's 22nd Annual Pain Therapeutics Conference.
About this update from Gb Sciences, Inc.
[{"type":"text","content":"\n LAS VEGAS, May 05, 2022 (GLOBE NEWSWIRE) -- Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences (OTCQB:GBLX), a leading plant-inspired biopharmaceutical research and development company, spoke today at Europe's leading pain therapeutics conference, SMi's 22nd Annual Pain Therapeutics Conference in London. Dr. Small-Howard's presentation can be viewed here in its entirety. \"Gb Sciences' plant-inspired therapeutics provide a promising new option for the treatment of chronic pain by targeting known pain receptors in the TRP family,\" said Dr. Small-Howard. \"Our cannabis-inspired formulations are performing well in preclinical studies, and we have additional plant-inspired formulations in the early stages of the drug development process.\" In the U.S. alone, chronic pain represents an estimated health burden of between $560 and $650 billion dollars, and an estimated 20.4% of U.S. adults suffer from chronic pain that significantly decreases their quality of life according to the Centers for Disease Control and Prevention (\"CDC\"). Despite the widespread rates of addiction and death, opioids remain the standard of care treatment for most people with chronic pain. The CDC reported that in 2020 over 142 million opioid prescriptions were dispensed in the U.S. Growing concerns have made the development of new pain medications, such as Gb Sciences' novel plant-inspired therapeutics, an important and promising field of research and development. Dr. Small-Howard's presentation, titled \"Novel Plant-Inspired Therapeutics for Pain,\" addressed their goal of re-imagining traditional plant-based medicines for the prescription drug market using Gb Sciences' proprietary, AI-driven drug discovery platform. PhAROS™ (Phytomedical Analytics for Research Optimization at Scale) is Gb Sciences' proprietary drug discovery platform that uses AI-enhanced data analytics and machine learning to identify and predict the efficacy of combinations of novel active ingredients from plants. PhAROS™ defines simplified therapeutic mixtures that retain the efficacy of whole plant therapies. PhAROS™ also predicts both the efficacy of these minimum essential mixtures, as well as their potential for side effects. Using cannabis-inspired pain therapeutics as a case study, Dr. Small-Howa...